智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300122 智飞生物

已收盘 09-03 15:00:00

{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":13.73,"timestamp":1788419034000,"preClose":13.64,"halted":0,"volume":37057878,"delay":0,"changeRate":0.0066,"floatShares":1414000000,"shares":2394000000,"eps":-6.2385,"marketStatus":"已收盘","change":0.09,"latestTime":"09-03 15:00:00","open":13.68,"high":13.92,"low":13.4,"amount":506000000,"amplitude":0.0381,"askPrice":13.74,"askSize":447,"bidPrice":13.73,"bidSize":342,"shortable":0,"etf":0,"ttmEps":-6.2385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788485400000},"marketStatusCode":5,"adr":0,"adjPreClose":13.64,"symbolType":"stock","openAndCloseTimeList":[[1788399000000,1788406200000],[1788411600000,1788418800000]],"highLimit":15,"lowLimit":12.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":2.17,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":-0.142384,"marketValue":32867000000,"turnoverRate":0.0262,"status":0,"floatMarketCap":19418000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2664817493","title":"智飞生物（300122）披露回购公司股份进展公告，9月2日股价下跌3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817493","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664817493?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:15","pubTimestamp":1788358521,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，智飞生物报收于13.64元，较前一交易日下跌3.4%，最新总市值为326.51亿元。该股当日开盘14.29元，最高14.29元，最低13.6元，成交额达6.15亿元，换手率为3.15%。智飞生物于2026年9月2日披露《关于回购公司股份的进展公告》。公告显示，公司于2026年7月20日召开第六届董事会第十二次会议，审议通过《关于回购公司股份方案的议案》，拟使用自有或自筹资金以集中竞价交易方式回购公司A股股份，用于股权激励或员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0188","LU1328615791.USD","LU2580892862.HKD","BK0196","BK0077","BK0239","300122","LU2580892789.USD","BK0046","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832774","title":"智飞生物(300122.SZ)：冻干人用狂犬病疫苗(ZFB-3细胞)临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832774","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664832774?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:05","pubTimestamp":1788253557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物(300122.SZ)发布公告，公司于近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的冻干人用狂犬病疫苗(ZFB-3细胞)获得国家药品监督管理局药物临床试验申请受理通知书。该药品用于预防狂犬病。通过接种该疫苗，可剌激机体产生抗狂犬病病毒的免疫力。该药品以公司自主研制的人二倍体细胞株(ZFB-3细胞)作为生产基质，与动物源性细胞狂犬病疫苗相比，理论上局部和全身不良反应发生率更小，且无致瘤性风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BMED","BK0046","IBBJ","PSYK","BK0196","300122","LU2148510915.USD","IBBQ","LU2580892789.USD","BK0188","LU1064130708.USD","159646","MDTX","LU1064131003.USD","LU2580892862.HKD","LU1328615791.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663200430","title":"智飞生物中报：现金流持续为正 首款治疗产品获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2663200430","media":"中金财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663200430?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:17","pubTimestamp":1788160623,"startTime":"0","endTime":"0","summary":"近日，智飞生物发布2026年半年报。报告期内，智飞生物坚定贯彻长期发展战略，纵深推进转型升级，强化风险防控体系，经营运行总体企稳。　　尽管短期承压，但从现金流和资产负债表来看，公司经营质量正在持续改善，成为半年报中值得关注的积极信号。　　报告期内，经营活动产生的现金流量净额19.74亿元，同比增长21.64%，已连续六个季度持续为正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260831/32354605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU2580892862.HKD","BK4585","LU2148510915.USD","LU1328615791.USD","LU2580892789.USD","BK4588","BK0196","SPHQ","BK0046","159399","BK0077","BK0188","LU1064130708.USD","BK0239","LU1064131003.USD","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663026994","title":"智飞生物半年报：利拉鲁肽商业化落地，预防+治疗双轮驱动重构成长逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2663026994","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663026994?lang=zh_cn&edition=full","pubTime":"2026-08-31 10:05","pubTimestamp":1788141901,"startTime":"0","endTime":"0","summary":"报告期内，在疫苗行业需求波动的大环境之下，公司在夯实经营基本盘同时，研发板块迎来标志性进展：首款治疗类产品利拉鲁肽注射液实现商业化，公司“预防+治疗”协同的战略布局取得阶段性突破，推动企业向创新产品驱动型生物制药企业转型。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788141840511723943","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU1064131003.USD","BK0188","LU1328615791.USD","LU2580892862.HKD","BK0196","BK0077","BK0239","300122","LU2580892789.USD","BK0046","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048783","title":"智飞生物（300122）2026年中报简析：净利润同比下降33.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048783","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048783?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:27","pubTimestamp":1788042458,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期智飞生物发布2026年中报。根据财报显示，智飞生物净利润同比下降33.35%。截至本报告期末，公司营业总收入40.24亿元，同比下降18.36%，归母净利润-8.09亿元，同比下降33.35%。本文数据来源于智飞生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663165012","title":"智飞生物(300122)8月20日股东户数11.14万户，较上期减少2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663165012","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663165012?lang=zh_cn&edition=full","pubTime":"2026-08-29 17:16","pubTimestamp":1787995006,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智飞生物披露，截至2026年8月20日公司股东户数为11.14万户，较8月10日减少2498.0户，减幅为2.19%。在生物制品行业个股中，智飞生物股东户数高于行业平均水平，截至8月20日，生物制品行业平均股东户数为3.54万户。根据统计，智飞生物2026年8月10日至2026年8月20日，主力资金净流入2.09亿元，游资资金净流出1.65亿元，散户资金净流出4351.29万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900023729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","300122","LU1064130708.USD","BK0196","LU2148510915.USD","BK0077","BK0188","LU1328615791.USD","BK0046","LU2580892789.USD","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013923","title":"图解智飞生物中报：第二季度单季净利润同比下降50.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013923","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663013923?lang=zh_cn&edition=full","pubTime":"2026-08-29 03:55","pubTimestamp":1787946946,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物2026年中报显示，上半年度公司主营收入40.24亿元，同比下降18.36%；归母净利润-8.09亿元，同比下降33.35%；扣非净利润-8.06亿元，同比下降29.53%；其中2026年第二季度，公司单季度主营收入18.74亿元，同比下降27.24%；单季度归母净利润-4.2亿元，同比下降50.4%；单季度扣非净利润-4.15亿元，同比下降46.09%；负债率45.05%，投资收益-231.46万元，财务费用1.62亿元，毛利率18.08%。财报数据概要请见下图:本文数据来源于智飞生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082900007710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191372482","title":"智飞生物上半年亏损8.085亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1191372482","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191372482?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:57","pubTimestamp":1787918260,"startTime":"0","endTime":"0","summary":"8月28日，路透社消息——智飞生物（300122.SZ）公布上半年业绩，净亏损达8.085亿元人民币，折合美元约1.2030亿。这家总部位于重庆的疫苗制造商，其财务表现引发了市场的广泛关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU1064130708.USD","LU1064131003.USD","LU2580892862.HKD","LU2148510915.USD","BK0239","BK0188","300122","BK0046","LU1328615791.USD","BK0077","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662693660","title":"智飞生物：该平台已支撑公司带状疱疹mRNA疫苗等多款在研项目有序推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2662693660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662693660?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911031,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司mRNA技术目前进展如何？有哪些相关成果？智飞生物回复：您好，目前公司已搭建“七+N”技术平台体系，其中包含mRNA技术平台。该平台已支撑公司带状疱疹mRNA疫苗等多款在研项目有序推进。公司研发项目的情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041839.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2580892789.USD","LU1328615791.USD","BK0077","LU1064131003.USD","BK0046","LU1064130708.USD","BK0188","BK0239","300122","LU2580892862.HKD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662695390","title":"智飞生物：公司持续开展产品创新，积极推动自主产品研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2662695390","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662695390?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911027,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：公司股价连跌了6年，从最高价231元跌到了11元，跌幅超97%居医药板块第一。公司主要营收靠代理美国的默沙东疫苗，但这类疫苗的市场份额逐步被国产疫苗替代。请问：代理的国外疫苗大量过期导致公司巨额亏损，公司靠什么扭转目前的局面呢？智飞生物回复：您好，公司持续开展产品创新，积极推动自主产品研发；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","LU2580892862.HKD","LU1064130708.USD","BK0046","300122","LU2148510915.USD","BK0077","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662543069","title":"智飞生物：贯彻“技术&市场”双轮驱动的发展策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2662543069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662543069?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:57","pubTimestamp":1787911027,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：根据诸多财经媒体报道，公司去年亏损147亿元居生物医药板块和创业板第一。进入2026年，公司的经营业绩没有一点好的趋势，反而亏损还在加大。请问：公司仅仅靠单一的代理国外疫苗为营收，这种经营模式还能持续多久？智飞生物回复：您好，公司贯彻“技术&市场”双轮驱动的发展策略，以专业、高效的市场团队推动优质产品释放商业价值，同时以市场推广成果反哺研发创新，形成相互促进的发展格局。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0077","BK0196","BK0239","LU2580892862.HKD","BK0046","LU2580892789.USD","LU1328615791.USD","LU1064130708.USD","BK0188","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662277404","title":"8月27日智飞生物涨5.86%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662277404","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662277404?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:52","pubTimestamp":1787820722,"startTime":"0","endTime":"0","summary":"证券之星消息，8月27日智飞生物涨5.86%创60日新高，收盘报15.0元，换手率8.23%，成交量116.4万手，成交额16.83亿元。重仓智飞生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700039345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1328615791.USD","562860","LU2580892789.USD","BK0046","BK0188","BK0196","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661827983","title":"智飞生物（300122）新增【免疫治疗】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2661827983","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661827983?lang=zh_cn&edition=full","pubTime":"2026-08-24 20:30","pubTimestamp":1787574619,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，8月24日智飞生物新增概念。智飞生物主营业务：疫苗、生物制品研发、生产、销售、配送及进出口。智飞生物2026年一季报显示，一季度公司主营收入21.5亿元，同比下降8.64%；归母净利润-3.88亿元，同比下降18.79%；扣非净利润-3.91亿元，同比下降15.62%；负债率45.99%，投资收益-231.46万元，财务费用8589.44万元，毛利率29.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400033542.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU2148510915.USD","LU1328615791.USD","LU2580892789.USD","BK0196","BK0046","BK0188","BK0077","LU1064130708.USD","LU1064131003.USD","BK0239","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221719","title":"8月24日智飞生物跌7.70%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661221719?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:39","pubTimestamp":1787560772,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日智飞生物跌7.70%，收盘报12.83元，换手率4.3%，成交量60.87万手，成交额8.06亿元。重仓智飞生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6919，较上一交易日下跌2.97%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","LU1064130708.USD","LU1328615791.USD","562860","BK0239","LU2580892789.USD","LU1064131003.USD","300122","LU2580892862.HKD","LU2148510915.USD","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660020554","title":"8月20日智飞生物涨19.97%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660020554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660020554?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:41","pubTimestamp":1787215316,"startTime":"0","endTime":"0","summary":"证券之星消息，8月20日智飞生物涨19.97%创60日新高，收盘报14.48元，换手率4.36%，成交量61.66万手，成交额8.93亿元。重仓智飞生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000028978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1328615791.USD","300122","LU1064131003.USD","LU2580892789.USD","562860","BK0046","LU1064130708.USD","LU2580892862.HKD","LU2148510915.USD","BK0188","BK0196","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660727484","title":"生物疫苗股全线大涨，康希诺等5股20CM涨停，默沙东莫德纳黑色素瘤疫苗临床试验传捷报","url":"https://stock-news.laohu8.com/highlight/detail?id=2660727484","media":"格隆汇","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660727484?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:47","pubTimestamp":1787190439,"startTime":"0","endTime":"0","summary":"8月20日，A股市场生物疫苗股全线大涨，其中，百克生物、康希诺、沃森生物、莱美药业、智飞生物20CM涨停，康华生物逼近20CM涨停，康泰生物涨超17%，华兰疫苗涨超10%，德展健康、双鹭药业、海普瑞、海欣股份、万泰生物10CM涨停，金迪克、博晖创新涨超7%，西藏药业、卫光生物、利德曼、冠昊生物、塞力医疗、赛升药业、申联生物、欧林生物涨超6%。消息面上，默沙东与莫德纳周三宣布，联合研发的黑色素瘤皮肤癌疫苗在首次晚期临床试验中取得积极初步结果。\n\n港股频道更多独家策划、专家专栏，免费查阅>>\n\n            责任编辑：栎树","market":"fut","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820094719181.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20094758182842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IE00BFTCPJ56.SGD","SG9999015358.SGD","LU2580892789.USD","BK4559","301207","LU1585245621.USD","IE00B1BXHZ80.USD","LU0320765489.SGD","688185","LU2023250843.SGD","MRNA","IE00BJJMRZ35.SGD","SG9999014575.USD","LU2580892862.HKD","LU1064131003.USD","XLV","BK4568","IE0002141913.USD","IHE","LU0432979614.USD","BK4139","IE00B2B36J28.USD","LU0289739699.SGD","BK4007","IE00BLSP4239.USD","LU1917777945.USD","SG9999002224.SGD","LU0689626769.HKD","LU2468319806.SGD","LU0823416689.USD","LU1941712264.USD","MRNX","SG9999002232.USD","LU0265550946.USD","LU0211331839.USD","LU2125154778.USD","LU0868494708.USD","IE00BJT1NW94.SGD","MRNY","LU2357627491.SGD","GDOC","BK4501","LU1066051498.USD","LU2361044865.SGD","LU1989772923.USD","BK0046","LU1061106388.HKD","IXJ","VHT","LU2125154935.USD","LU1064130708.USD","LU2089984988.USD","JDOC","IDNA","LU2433249047.HKD","SG9999014567.USD","688276","LU0648001328.SGD","LU0098860793.USD","LU1934455194.USD","SG9999001176.SGD","LU1066053197.SGD","LU0985320562.USD","LU2361044949.HKD","LU0965508806.USD","LU0965509283.SGD","LU1430594728.SGD","LU1941712348.USD","IE00BSNM7G36.USD","IE000M9KFDE8.USD","LU1116320737.USD","LU1929549753.HKD","LU1989772840.SGD","SG9999001440.SGD","300006","IE00BLSP4452.SGD","LU1037948897.HKD","BK4516","LU0106261372.USD","LU2148510915.USD","LU0122379950.USD","BK0188","LU0130517989.USD","LU0058720904.USD","LU0203345920.USD","BK0239","PAWZ","LU0070302665.USD","GNOM","LU2491050071.SGD","LU1066051811.HKD","IE0009355771.USD","LU0859254822.USD","LU2361045086.USD","LU1093756325.SGD","LU2324357040.USD","BK0070","FHLC","BK4588","BK4585","LU0942090050.USD","LU1974910355.USD","SG9999014559.SGD","BK0196","LU0320765646.SGD","LU0965509010.AUD","LU1291159041.SGD","LU1983299246.USD","PPH","LU0266013472.USD","300142","BK4532","IYH","IE00BN8TJ469.HKD","LU2023250504.SGD","BK4533","LU1057294990.SGD","LU2491049909.HKD","LGHT","LU1116320901.HKD","LU0208291251.USD","SG9999015341.SGD","SG9999013999.USD","LU1035773651.USD","LU1934455863.HKD","BK4550","TRUH","LU2106854487.HKD","LU1201861249.SGD","SGXZ57979304.SGD","BK0077","LU2125909247.SGD","LU1066051225.USD","BK4551","LU1162221912.USD","LU1989771016.USD","LU0868494617.USD","06185","MRK","LU1923622614.USD","LU0477156953.USD","FTXH","LU2491050154.USD","LU2125909593.SGD","LU1069347547.HKD","LU0265550359.USD","LU2112291526.USD","RXL","LU1328615791.USD","BK4548","LU1571399168.USD","LU2461242641.AUD","WDNA","LU0124676726.USD","LU0861579265.USD","LU0130102774.USD","LU0965509101.SGD","SG9999014542.SGD","LU0980610538.SGD","LU1023059063.AUD","LU1093756168.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","BK4534","300122","LU0006306889.USD","LU1934455277.USD","LU0238689110.USD","LU0234572021.USD","HRTS","LU2360032135.SGD","SG9999001176.USD","LU0203347892.USD","LU1699723380.USD","LU1037948541.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660217037","title":"股市必读：智飞生物（300122）8月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660217037","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660217037?lang=zh_cn&edition=full","pubTime":"2026-08-17 01:38","pubTimestamp":1786901890,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，智飞生物报收于13.06元，下跌1.21%，换手率1.96%，成交量27.73万手，成交额3.62亿元。董秘： 您好，截至2026年8月10日，公司普通股股东人数为113,869，谢谢！截止2026年8月8日，公司股价为13.48元／股，较质押预警线涨跌幅为﹣52.20%,较质押平仓线涨跌幅为﹣45.37%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700000587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","300122","LU2580892789.USD","LU1328615791.USD","LU2148510915.USD","BK0196","BK0239","BK0046","LU1064131003.USD","BK0188","BK0077","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659296112","title":"智飞生物：专一专注专业深耕生物制药领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2659296112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659296112?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698388,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，近期生物制药领域各大公司股价都大幅上涨，贵公司股价却停滞不前，其原因是什么？该如何扭转当前局面？智飞生物回复：您好，二级市场股票价格受多种因素影响。公司专一、专注、专业地在生物制药领域深耕，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。公司的发展情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0077","BK0188","LU1064131003.USD","300122","BK0196","BK0046","LU2580892789.USD","03069","LU1064130708.USD","LU1328615791.USD","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659112257","title":"智飞生物：聚焦生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2659112257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659112257?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698386,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，根据智飞长期在股票市场的表现，是否可以考虑主动申请退市？安心做产品研究开发。这样对公司对投资者都是比较中肯的选择，因为公司已经不具备跟同行业的大中小公司的竞争能力。智飞生物回复：您好，公司聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。公司的发展情况请您关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU2148510915.USD","LU2580892789.USD","LU1064131003.USD","LU1064130708.USD","300122","BK0239","BK0196","BK0046","LU1328615791.USD","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659111226","title":"智飞生物：公司专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2659111226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659111226?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698384,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)08月14日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，市场很多投资者因为选择投资智飞生物而后悔不已，这种消极的情绪和言传口碑，是否会直接或间接影响公司产品在全国各地的销售？针对这种连锁负反馈，公司是否制定相关措施来制止或弥补这一情况的发生？！请详细回答一下智飞生物回复：您好，二级市场股票价格受多种因素影响。公司专一、专注、专业地在生物制药领域深耕，为民众提供优质产品。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400028160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","03069","BK0239","LU2148510915.USD","BK0046","300122","LU2580892789.USD","BK0188","LU1064131003.USD","LU2580892862.HKD","BK0196","LU1064130708.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788470596481,"stockEarnings":[{"period":"1week","weight":-0.0847},{"period":"1month","weight":0.0394},{"period":"3month","weight":0.1037},{"period":"6month","weight":-0.1504},{"period":"1year","weight":-0.3702},{"period":"ytd","weight":-0.2724}],"compareEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":0.0313},{"period":"3month","weight":-0.0213},{"period":"6month","weight":-0.0442},{"period":"1year","weight":0.0337},{"period":"ytd","weight":-0.0067}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111371人(较上一季度减少2.19%)","perCapita":"12699股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":"　　重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、流感病毒裂解疫苗、达舒宸、佳达修9、乐儿德、纽莫法、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}